Table 5.
Injection-site reactions by monthly dosing interval among pooled galcanezumab-treated participants in CGAJ and REGAIN studies, ≥1% incidence (galcanezumab exposure analysis set)
| Participants with ≥ 1 ISRs | Total, n (%) |
|---|---|
| N | 1326 |
| IS pain | 108 (8.1) |
| Unspecified ISRs | 103 (7.8) |
| IS erythema | 62 (4.7) |
| IS pruritus | 30 (2.3) |
| IS bruising | 25 (1.9) |
| IS rash | 18 (1.4) |
| IS hematoma | 14 (1.1) |
Abbreviations:IS injection-site, ISR injection-site reaction, N number of galcanezumab-treated participants, n number of participants within each specific category
Note: All values are for ISRs from study start up to 12 months for REGAIN and CGAJ studies; pooled galcanezumab = galcanezumab 120 mg + galcanezumab 240 mg